Skip to main content

Table 4 Comparison of clinical symptom disappearance rate between Ludangshen and placebo group

From: Ludangshen oral liquid for treatment of convalescent COVID-19 patients: a randomized, double-blind, placebo-controlled multicenter trial

Variables

FAS analysis

PPS analysis

Ludangshen

Placebo

P value

Ludangshen

Placebo

P value

Fatigue (n)

94

90

 

92

89

 

 Week 1

5 (5.3)

0 (0.0)

0.027

5 (5.4)

0 (0.0)

0.026

 Week 2

35 (5.3)

8 (8.9)

 < 0.001

34 (36.7)

8 (9.0)

 < 0.001

Anorexia (n)

68

70

 

67

68

 

 Week 1

10 (14.7)

3 (4.3)

0.036

10 (14.9)

3 (4.4)

0.038

 Week 2

39 (57.4)

15 (21.4)

 < 0.001

39 (58.2)

14 (20.6)

 < 0.001

Distention (n)

43

34

 

42

33

 

 Week 1

10 (23.3)

4 (11.8)

0.194

10 (23.8)

4 (12.1)

0.197

 Week 2

29 (67.4)

12 (35.3)

0.005

29 (69.1)

11 (33.3)

0.002

Loose stools (n)

48

52

 

48

50

 

 Week 1

11 (22.9)

5 (9.6)

0.07

11 (22.9)

5 (10.0)

0.058

 Week 2

32 (66.7)

20 (38.5)

0.005

32 (66.7)

18 (36.0)

0.002

Shortness of breath (n)

50

50

 

49

49

 

 Week 1

0 (0.0)

0 (0.0)

1.000

0 (0.0)

0 (0.0)

1.000

 Week 2

8 (16.0)

3 (6.0)

0.110

8 (16.3)

3 (6.1)

0.110

  1. FAS full analysis set, PPS per protocol set